Fredrik Pontén

Title: Fredrik Pontén: Innovator in Colorectal Cancer Research

Introduction

Fredrik Pontén is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of cancer research, particularly in colorectal cancer. With a total of 9 patents to his name, his work focuses on innovative methods for cancer prognosis.

Latest Patents

Pontén's latest patents include groundbreaking methods for determining the prognosis of colorectal cancer patients. One of his notable inventions is related to the PODXL protein. This patent outlines a method for evaluating the amount of PODXL protein in a sample from a mammalian subject. By comparing this value to a predetermined reference, the method helps classify patients into two groups based on their prognosis.

Another significant patent involves the RBM3 protein. This invention provides a method for assessing whether a colorectal cancer patient belongs to a group with a better or worse prognosis. Similar to the PODXL method, it evaluates the amount of RBM3 protein or mRNA in a sample and compares it to a reference value to determine the patient's classification.

Career Highlights

Fredrik Pontén is currently associated with Atlas Antibodies AB, where he continues to advance his research in cancer diagnostics. His work has been instrumental in developing methods that can potentially improve patient outcomes in colorectal cancer.

Collaborations

Pontén has collaborated with esteemed colleagues such as Mathias Uhlén and Karin Jirström. These partnerships have further enriched his research and contributed to the development of innovative cancer prognostic methods.

Conclusion

Fredrik Pontén's contributions to colorectal cancer research through his patents and collaborations highlight his commitment to improving cancer diagnostics. His innovative methods have the potential to significantly impact patient care and prognosis in the field of oncology.